Bicara Therapeutics Inc. Common Stock (BCAX) Free Cash Flow
Bicara Therapeutics Inc. Common Stock (BCAX) free cash flow history and trends. Track FCF in Excel with MarketXLS.
Free Cash Flow Data
| Period | Free Cash Flow (USD) |
|---|---|
| 2022-12-31 | -$32.27M |
| 2023-12-31 | -$59.62M |
| 2024-12-31 | -$74.82M |
| 2025-12-31 | -$107.11M |
How BCAX compares with sector peers
| Symbol | Company | Free cash flow (latest fiscal year) |
|---|---|---|
| IMUX | Immunic Inc. | -$85.97M |
| AXSM | Axsome Therapeutics Inc. | -$93.89M |
| VNDA | Vanda Pharmaceuticals Inc. | -$110.44M |
| FLGT | Fulgent Genetics Inc. | -$124.21M |
| RGNX | REGENXBIO Inc. | -$126.38M |
These are five companies in the same sector as BCAX with a comparable annual free cash flow. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Bicara Therapeutics Inc. Common Stock Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Free_Cash_Flow("BCAX", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | BCAX | $17.63 | -3.13% | 0.76M |
| 3 | ||||
| 4 | ||||
| 5 |